Finance entity
AtriCure is most often covered alongside EQT Corporation, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 208-day span. Each story carries 4 original sources on average, compared with 2.7 for the broader beat in this window.
Last mentioned: 9h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AtriCure is most often covered alongside EQT Corporation, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 208-day span. Each story carries 4 original sources on average, compared with 2.7 for the broader beat in this window. The 5.5 average consequence score is below the beat benchmark of 6.2 in the same window. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Finance stories that mention AtriCure, published between February 18, 2026 and September 13, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 4870 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AtriCure. Shared-story counts are live from our verified record — not editorial picks.
CTO executes sale of 3,657 shares
Privitera sold 3,657 shares at a weighted average price of $55, generating approximately $201,135.
AtriCure closes at $53.73
Post-transaction stock close values Privitera's remaining ~147,000 shares at about $7.9 million.
Rule 10b5-1 trading plan adopted
Salvatore Privitera established a pre-arranged trading plan for future stock sales, setting execution terms months before the September transaction.
AtriCure's CTO sold $201,135 in stock at $55 per share as ATRC rallied 49% over 12 months. The 10b5-1 plan reduces negative signaling, but the sale raises valuation questions amid thin net margins.
Source: Jack Delaney (us) · fool.com
A diverse group of mid-to-large cap companies across mining, energy, and healthcare reported stronger-than-expected quarterly results, signaling robust operational efficiency. IAMGOLD and EQT Corporation headlined the session with significant revenue outperformance, reflecting strength in commodity and energy markets.
AtriCure is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
